Does dupilumab treatment increase SARS-CoV-2 infection
susceptibility?
Dupilumab is approved for the treatment of moderate-to-severe atopic
dermatitis. First data from Italy on dupilumab-treated non-infected in
high epidemic areas, and current evidence from dupilumab trials, suggest
no negative effect of dupilumab regarding viral
infections151 with reports on a reduced number of
herpes simplex superinfections and less bacterial
superinfections.152-154